Latest News and Press Releases

Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer.

•    Ecuador aims to become one of the first rabies free countries in Latin America.•    Joint efforts with the Ministry of Public Health focus on vaccination, education and epidemiological...

Intended audience: global business, financial and trade media HERNEXEOS® (zongertinib) and JASCAYD® (nerandomilast) launched in H2, 2025Group net sales increased 7.3%* to EUR 27.8 billion in...

43% of pet owners report that their pets experienced parasite infections, with 75% looking for clearer parasite prevention advice.Veterinarians are seen as the most trusted source of pet health...

This press release is not intended for UK media HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1...

Boehringer and Sitryx Therapeutics partner to advance autoimmune and inflammatory disease research for more personalized, targeted, data driven treatment.

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with...

Boehringer partners with Simcere to develop a bispecific antibody that simultaneously inhibits two drivers of inflammatory bowel disease.

Boehringer launches clinical trial exploring interleukin-11’s potential to go beyond slowing IPF and restore lung function.

Boehringer and Jazz Pharma partner to combine two unique HER2-targeted approaches, aiming to offer new breast cancer treatment options.